|
Novel Abiraterone Conjugate with lower liver toxicity and high oral bioavailability
|
Oncology/Cancer
|
Prostate cancer
|
PCC
|
Global
| |
|
A 4th Generation ALK selective, brain penetrant, TRK-sparing Tyrosine Kinase Inhibitor
|
Oncology/Cancer
|
Solid tumor (ALK+ NSCLC)
|
PCC
|
Global
| |
|
A potent dual PARP7/PARP12 inhibitor
|
Oncology/Cancer
|
Lung cancer,Colorectal cancer
|
PCC
|
Global
| |
|
anti-CCL17 mAb
|
Immunological disease
|
Moderate to severe knee osteoarthritis pain,Chronic pain
|
PCC
|
Global
| |
|
Best-in-class BCL-XL PROTAC
|
Ophthalmology disease
|
Ocular fundus pathology,DME,DR
|
PCC
|
Global
| |
|
Best-in-class Lp(a) siRNA
|
Cardiovascular
|
Atherosclerosis
|
PCC
|
Global
| |
|
Best-in-class RIPK2 PROTAC: a Novel therapeutic approach for Inflammatory bowel disease
|
Immunological disease
|
Inflammatory bowel disease
|
PCC
|
Global
| |
|
First-in-class (FIC) ER stress modulator
|
|
|
PCC
|
| |
|
GPCR selective agonist
|
Immunological disease
|
Duchenne muscular dystrophy,Systemic lupus erythematous;,Ulcerative colitis;,Ankylosing spondylitis
|
PCC
|
Global
| |
|
Highly potent and selective 2nd-gen RET inhibitor against wild-type and broad-acquired drug-resistant mutant cancers
|
|
|
PCC
|
| |
|
Novel selective inhibitor for Autoimmune disease therapy
|
|
|
PCC
|
| |
|
See in our "Antibody Licensing" platform
|
|
Next to "Licensing" Tab in the top
|
PCC
|
| |
|
Selective POLQ inhibitor
|
Oncology/Cancer
|
Pancreatic cancer,BRCAm ,other DDR-deficient tumors
|
PCC
|
Global
| |
|
siRNA drug targeting Inhibin beta E (INHBE)
|
Immunological disease
|
Obesity
|
PCC
|
Global
| |
|
Small Molecule Antagonist of APP–SIGMAR1 Interaction
|
Neurological disease
|
Early Alzheimer's Disease
|
PCC
|
Global
| |
